Dr. James Shannon has extensive expertise in drug development and (big) pharma. From 2012 until his retirement in 2015, James was Chief Medical Officer at GlaxoSmithKline. Prior to that he was Global Head of Pharma Development at Novartis and Senior Vice-President, Clinical Development at Sterling Winthrop Pharmaceuticals. He held board positions at companies including Biotie, Circassia, Crucell, Endocyte and Cerimon Pharmaceuticals. He currently is Chairman of myTomorrows and Kyowa Kirin (NA) and sits on the Board of Horizon Therapeutics, Mannkind and Immodulon. He received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK).